Drugmaker with rare disease work · based in San Diego, United States · founded 2002 · ticker GYRE · gyretx.com
Gyre Therapeutics, formerly Catalyst Biosciences, completed a business combination in October 2023 and now operates as a biopharmaceutical company focused on fibrotic and inflammatory diseases. The company develops therapies for liver fibrosis and other fibrotic conditions. Catalyst Biosciences once tested hemophilia medicines, and every one of those trials has ended.
We did not find active Gyre Therapeutics (formerly Catalyst Biosciences) trials for the rare diseases we track on ClinicalTrials.gov right now.
More about Gyre Therapeutics (formerly Catalyst Biosciences)
Gyre completed its all-stock acquisition of Cullgen Inc., valued at approximately $300 million, on May 4, 2026, adding a targeted protein degradation platform. Cullgen CEO Ying Luo became Gyre's president and CEO.
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Gyre Therapeutics (formerly Catalyst Biosciences)'s own site is gyretx.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Questions about Gyre Therapeutics (formerly Catalyst Biosciences)
Gyre Therapeutics, formerly Catalyst Biosciences, completed a business combination in October 2023 and now operates as a biopharmaceutical company focused on fibrotic and inflammatory diseases. The company develops therapies for liver fibrosis and other fibrotic conditions. Catalyst Biosciences once tested hemophilia medicines, and every one of those trials has ended. Gyre completed its all-stock acquisition of Cullgen Inc., valued at approximately $300 million, on May 4, 2026, adding a targeted protein degradation platform. Cullgen CEO Ying Luo became Gyre's president and CEO.
Gyre Therapeutics (formerly Catalyst Biosciences) is a diversified pharmaceutical company headquartered in San Diego, United States, founded in 2002. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 0 active rare disease programs. Many of its rare disease treatments hold orphan drug designations from the FDA.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Gyre Therapeutics (formerly Catalyst Biosciences), pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
None that we track as of November 2026. No Gyre Therapeutics (formerly Catalyst Biosciences) label in the FDA's openFDA database matches a rare disease on Trial Friend, which usually means the company has no approved product yet or its approved drugs are for common conditions.
In development: the trials list on this page shows what Gyre Therapeutics (formerly Catalyst Biosciences) is recruiting for now, and the FDA calendar lists any application once a decision date is public.
Gyre Therapeutics (formerly Catalyst Biosciences) was founded in 2002 and is headquartered in San Diego, United States. The company has been active for 24 years. It trades publicly under the ticker symbol GYRE.